The role of lipoprotein(a) in coronavirus disease 2019 (COVID-19) with relation to development of severe acute kidney injury
Abstract Lipoprotein(a) (Lp(a)) is a prothrombotic and anti-fibrinolytic lipoprotein, whose role has not been clearly defined in the pathogenesis of coronavirus disease 2019 (COVID-19). In this prospective observational study, serum Lp(a) as well as outcomes were measured in 50 COVID-19 patients and 30 matched sick controls. Lp(a) was also assessed for correlation with a wide panel of biomarkers. Serum Lp(a) did not significantly differ between COVID-19 patients and sick controls, though its concentration was found to be significantly associated with severity of COVID-19 illness, including acute kidney failure stage (r = 0.380, p = 0.007), admission disease severity (r = 0.355, p = 0.013), and peak severity (r = 0.314; p = 0.03). Lp(a) was also positively correlated with interleukin (IL)-8 (r = 0.308; p = 0.037), fibrinogen (r = 0.344; p = 0.032) and creatinine (r = 0.327; p = 0.027), and negatively correlated with ADAMTS13 activity/VWF:Ag (r = − 0.335; p = 0.021); but not with IL-6 (r = 0.241; p = 0.106). These results would hence suggest that adverse outcomes in patients with COVID-19 may be aggravated by a genetically determined hyper-Lp(a) state rather than any inflammation induced elevations..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:53 |
|---|---|
| Enthalten in: |
Journal of thrombosis and thrombolysis - 53(2021), 3 vom: 28. Okt., Seite 581-585 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lippi, Giuseppe [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Acute kidney injury |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021 |
|---|
| doi: |
10.1007/s11239-021-02597-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR046707468 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR046707468 | ||
| 003 | DE-627 | ||
| 005 | 20230519144316.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220409s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11239-021-02597-y |2 doi | |
| 035 | |a (DE-627)SPR046707468 | ||
| 035 | |a (SPR)s11239-021-02597-y-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lippi, Giuseppe |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The role of lipoprotein(a) in coronavirus disease 2019 (COVID-19) with relation to development of severe acute kidney injury |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021 | ||
| 520 | |a Abstract Lipoprotein(a) (Lp(a)) is a prothrombotic and anti-fibrinolytic lipoprotein, whose role has not been clearly defined in the pathogenesis of coronavirus disease 2019 (COVID-19). In this prospective observational study, serum Lp(a) as well as outcomes were measured in 50 COVID-19 patients and 30 matched sick controls. Lp(a) was also assessed for correlation with a wide panel of biomarkers. Serum Lp(a) did not significantly differ between COVID-19 patients and sick controls, though its concentration was found to be significantly associated with severity of COVID-19 illness, including acute kidney failure stage (r = 0.380, p = 0.007), admission disease severity (r = 0.355, p = 0.013), and peak severity (r = 0.314; p = 0.03). Lp(a) was also positively correlated with interleukin (IL)-8 (r = 0.308; p = 0.037), fibrinogen (r = 0.344; p = 0.032) and creatinine (r = 0.327; p = 0.027), and negatively correlated with ADAMTS13 activity/VWF:Ag (r = − 0.335; p = 0.021); but not with IL-6 (r = 0.241; p = 0.106). These results would hence suggest that adverse outcomes in patients with COVID-19 may be aggravated by a genetically determined hyper-Lp(a) state rather than any inflammation induced elevations. | ||
| 650 | 4 | |a Lipoprotein(a) |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Coronavirus disease 2019 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Acute kidney injury |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Coagulopathy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Thrombosis |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Szergyuk, Ivan |4 aut | |
| 700 | 1 | |a de Oliveira, Maria Helena Santos |4 aut | |
| 700 | 1 | |a Benoit, Stefanie W. |4 aut | |
| 700 | 1 | |a Benoit, Justin L. |4 aut | |
| 700 | 1 | |a Favaloro, Emmanuel J. |4 aut | |
| 700 | 1 | |a Henry, Brandon Michael |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of thrombosis and thrombolysis |d Dordrecht [u.a.] : Springer Science + Business Media B.V, 1994 |g 53(2021), 3 vom: 28. Okt., Seite 581-585 |w (DE-627)SPR018007317 |w (DE-600)2017305-2 |x 1573-742X |7 nnns |
| 773 | 1 | 8 | |g volume:53 |g year:2021 |g number:3 |g day:28 |g month:10 |g pages:581-585 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11239-021-02597-y |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 53 |j 2021 |e 3 |b 28 |c 10 |h 581-585 | ||